A narrative review of pharmacologic approaches to symptom management of pediatric patients diagnosed with anti-NMDA receptor encephalitis

J Pediatr Rehabil Med. 2021;14(3):333-343. doi: 10.3233/PRM-200677.

Abstract

Anti-N-Methyl-D-Aspartate Receptor Encephalitis (ANMDARE) is one of the most common autoimmune encephalitis in the pediatric population. Patients with ANMDARE initially present with a prodrome of neuropsychiatric symptoms followed by progressively worsening seizures, agitation, and movement disorders. Complications can include problems such as aggression, insomnia, catatonia, and autonomic instability. Due to the complexity of this disease process, symptom management can be complex and may lead to significant polypharmacy. The goal of this review is to educate clinicians about the challenges of managing this disorder and providing guidance in symptom management.

Keywords: ANMDARE; Anti-NMDA receptor encephalitis; behavior; pharmacology; treatment.

Publication types

  • Review

MeSH terms

  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / diagnosis
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / drug therapy
  • Catatonia*
  • Child
  • Hashimoto Disease*
  • Humans
  • Movement Disorders*